Amgen (AMGN) Wins Ruling in Bid to Block Generic Otezla Until 2028, Loses Ruling on Otezla Patent That Expires in 2034 - Bloomberg
- Wall St ends up with Goldman; Dow posts biggest weekly rise since June
- Goldman Sachs (GS) Smashes Analyst 3Q Views on Robust M&A and Underwriting Activity
- Tesla (TSLA) Stock: Jefferies Raises Price Target on Higher Capacity Ramp and Sustained Demand, Berlin Giga Will Set New Design and Assembly Standards Says Analyst
- Food, fuels lift U.S. import prices in September
- SEC to Allow First Ever Bitcoin (BTC) ETF - Report
Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.
Amgen (NASDAQ: AMGN) Wins Ruling in Bid to Block Generic Otezla Until 2028, Loses Ruling on Otezla Patent That Expires in 2034 - Bloomberg
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UPDATE: Hertz Global Holdings (HTZZ) Files Up to $100M Share Offering by Selling Stockholders; Intends to Uplist to Nasdaq Under Ticker "HTZ"
- Perficient (PRFT) Announces Acquisition of Overactive
- Avadel Pharma (AVDL) Announces the FDA Review of NDA for FT218 for Patients with Narcolepsy is Still Ongoing
Create E-mail Alert Related CategoriesCorporate News, Litigation
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!